FDCP
CRSP icon

Foster Dykema Cabot & Partners’s CRISPR Therapeutics CRSP Stock Holding History

Foster Dykema Cabot & Partners’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$545 Hold
10
– – ﹤0.01% 316
2026
Q1 		$476 Hold
10
– – ﹤0.01% 317
2025
Q4 		$524 Hold
10
– – ﹤0.01% 323
2025
Q3 		$648 Hold
10
– – ﹤0.01% 409
2025
Q2 		$486 Hold
10
– – ﹤0.01% 334
2025
Q1 		$340 Hold
10
– – ﹤0.01% 331
2024
Q4 		$394 Hold
10
– – ﹤0.01% 368
2024
Q3 		$470 Hold
10
– – ﹤0.01% 496
2024
Q2 		$540 Hold
10
– – ﹤0.01% 312
2024
Q1 		$682 Hold
10
– – ﹤0.01% 309
2023
Q4 		$626 Buy
+10
New +$553 ﹤0.01% 271

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Foster Dykema Cabot & Partners's CRSP Position: Q2 2026 in Review

Foster Dykema Cabot & Partners held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 10 shares worth $545. The position accounts for ﹤0.01% of the portfolio, ranked #316.

Foster Dykema Cabot & Partners first reported a position in CRSP in Q4 2023 and has held it in 11 quarters since. The position peaked at $682 in Q1 2024. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Foster Dykema Cabot & Partners held 10 shares of CRISPR Therapeutics worth $545 as of Q2 2026.
  • Foster Dykema Cabot & Partners left its CRISPR Therapeutics share count unchanged in Q2 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Foster Dykema Cabot & Partners's portfolio in Q2 2026, its #316 holding.
  • Foster Dykema Cabot & Partners first reported a position in CRISPR Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • Foster Dykema Cabot & Partners's CRISPR Therapeutics position peaked at $682 in Q1 2024.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Foster Dykema Cabot & Partners's 13F filing for Q2 2026, filed 11 Aug 2026.